© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#EASL 2012
Click Here for More Conferences
Click Here for EASL.eu
An Introduction to Hepatitis

Interferon-Free BMS Combo Yields 77% Cure Rate in Geno 1 Hep C

A 24-week, interferon-free regimen pairing two drugs from Bristol-Myers Squibb--60 milligrams (mg) of daclatasvir, a once-daily NS5a...

PILOT Study: Three-Month Interferon-Free Regimen Cures 9 of 11 Geno 1, IL-28B CC Hep C Patients

A 12-week, interferon-free combination of two experimental, once-daily drugs--ABT-450/r, a Norvir (ritonavir)-boosted hepatitis C protease inh...

COPILOT Study: Second Three-Month Inteferon-Free Abbott Regimen Versus Geno 1 Hep C

A 12-week regimen of ribavirin plus two experimental drugs from Abbott Laboratories--ABT-450, a once-daily hepatitis C protease inhibitor boos...

MUST read

Hepatitis C: The Basics
Hepatitis B: The Basics
Hepatitis A: The Basics

Efficacy of 12-Week GS-7977/Ribavirin Combo for Hep C Geno 1 Varies by IL-28B Status

Early follow-up data from small evaluations of Gilead Sciences’ nucleotide analog GS-7977 plus ribavirin in people with genotype 1 hepa...

Interferon-Free Gilead and BMS Combo Shows High Cure Rate Potential

All-oral treatment with 24 weeks of daclatasvir, Bristol-Myers Squibb’s once-daily NS5a inhibitor, and GS-7977, Gilead’s once-daily...

Novel Lambda Peg-Interferon Has Safety Edge Over Approved Peg-Interferon

A novel version of interferon, pegylated interferon lambda-1a (peg-IFN-lambda), combined with ribavirin cured up to three-quarters of...

Hot topics

Forums: Support and discussion
Blogs: The community speaks

90% Geno 1 Patients Nearing Cure in 7977/Interferon Study

Ninety percent of people with genotype 1 hepatitis C virus (HCV) starting therapy for the first time show a clear sign of being cured of their...

TMC435 Boosts Cure Rates in Previously Treated Geno 1 HCV Patients

Up to 80 percent of people with genotype 1 hepatitis C virus (HCV) who didn’t respond successfully to earlier therapy were cured of their infe...

Victrelis Shows Effectiveness for Prior Treatment Null Responders

Additional data from a Merck-sponsored clinical trial help clarify the efficacy of Victrelis (boceprevir) combined with pegylated interferon a...
Advertisement
Treatment News
Newsfeed
Features
Ask Hep